This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
Insulin glargine/lixisenatide, sold under the brand name Soliqua 100/33 among others, is a fixed-dose combination medication that combines insulin glargine and lixisenatide and is used to treat diabetes. The most common side effects include hypoglycemia (low blood glucose), diarrhea, vomiting and nausea (feeling sick). Insulin glargine/lixisenatide was approved for medical use in the United States in November 2016, and in the European Union in January 2017.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:alternativeName |
|
| dbo:casNumber |
|
| dbo:kegg |
|
| dbo:wikiPageExternalLink | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink |
|
| dbp:atcPrefix |
|
| dbp:atcSuffix |
|
| dbp:casNumber |
|
| dbp:class |
|
| dbp:component |
|
| dbp:kegg |
|
| dbp:legalCa |
|
| dbp:legalEu |
|
| dbp:legalUs |
|
| dbp:pregnancyAu |
|
| dbp:routesOfAdministration | |
| dbp:synonyms |
|
| dbp:tradename |
|
| dbp:type |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |